PRESS RELEASE published on 01/26/2024 at 14:00, 9 months 25 days ago Optimind Pharma - Debenture Conversion Optimind Pharma Corp. (CSE:OMND) announces agreement to convert $303,750 convertible debentures at $0.025/share, potentially issuing 23,333,500 shares. Optimind focuses on psychedelic therapies for mental health. Convertible Debentures Optimind Pharma Corp. CSE:OMND Psychedelic Therapies Mental Health
PRESS RELEASE published on 12/19/2023 at 13:30, 11 months 1 day ago Optimind Pharma Provides Corporate Update
Published on 11/21/2024 at 10:03, 47 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 50 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 50 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 15 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 25 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:30, 19 minutes ago MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 45 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 47 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 49 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 49 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 06:58, 3 hours 52 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 29 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 5 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 5 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
